Medline reported revenue of $28.43 billion for fiscal year 2025 (ended December 31, 2025). Net income was $1.16 billion, a net margin of 4.1%, and diluted earnings per share were -$0.01.
At the end of fiscal year 2025 it had total assets of $38.48 billion, total liabilities of $19.20 billion and shareholders' equity of $10.74 billion, with cash and short-term investments of $1.94 billion and total debt of $12.63 billion.
Its operations brought in $1.74 billion of cash; capital spending was $447.00 million, leaving free cash flow of $1.30 billion.
The tables below show the income statement, balance sheet and cash flow statement; the key figures of the last 4 fiscal years are at the bottom of the page.
Figures from company filings, in USD; latest fiscal year ended December 31, 2025.

Annual • USD
| FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|
| Revenue | $28.4B | – | – | – |
| Gross profit | $7.5B | – | – | – |
| Operating income | $2.2B | – | – | – |
| Net income | $1.2B | – | – | – |
| Diluted EPS | -$0.01 | $0.66 | $0.13 | -$0.01 |
| Total assets | $38.5B | – | – | – |
| Total liabilities | $19.2B | – | – | – |
| Shareholders' equity | $10.7B | $16.5B | $55.0M | – |
| Cash and short-term investments | $1.9B | – | – | – |
| Total debt | $12.6B | – | – | – |
| Operating cash flow | $1.7B | – | – | – |
| Capital spending | $447.0M | – | $275.0M | – |
| Free cash flow | $1.3B | – | $1.4B | – |
In USD. Fiscal years as reported by the company; statements on this page go back to fiscal year 2022.
$28.43 billion.
Medline reported net income of $1.16 billion for fiscal year 2025 (4.1% of revenue); operating income was $2.21 billion.
At the end of fiscal year 2025: cash and short-term investments of $1.94 billion and total debt of $12.63 billion.
$1.30 billion in fiscal year 2025 (operating cash flow of $1.74 billion minus capital spending of $447.00 million).